HUNTSVILLE, Ala. (WAFF) - There is now an FDA-approved alternative to the EpiPen. A new nasal spray, called Neffy, can be used by people to treat severe allergic reactions. The new spray has ...

“There are a few things that can interfere with the effectiveness of an EpiPen,” Dr. Travis Stork, an ER physician, host of The Doctors and a member of PEOPLE’s Health Squad, says. The first ...

The furore over Mylan’s ‘price gouging’ in relation to EpiPen in the US went global, thanks to social media. Daniel Ghinn examines the reaction of healthcare professionals on social media ...

EpiPen users can expect to see Neffy hitting the shelves about eight weeks after it was approved, so sometime in early October 2024. Neffy not only brings a new delivery method to the market ...

Mylan's settlement with drug wholesalers comes on the heels of the company reaching a $264 million settlement for consumers and insurers. Pfizer also agreed to settlements in similar cases, including ...

The proposed settlement would end an ongoing lawsuit against Viatris Inc. (formerly Mylan), the makers of EpiPen, that began in 2016 after public outrage over the company's decision to raise the ...

SEE ALSO: How social media amplified anger over EpiPen's price gouge In a blog post on his company's website, Saunders didn't directly name Mylan, but said he condemns dramatic price increases in ...

Sanofi claims its Auvi-Q, a more portable epinephrine autoinjector with a retractable needle and audio instructions, couldn't compete on the unlevel playing field Mylan created for its EpiPen. (CN) — ...

There's a very good reason why the EpiPen's 500% price increase drew so much attention, even though there are other emergency auto-injecting devices available that can be used to treat severe ...

You'd think one scandal would be enough. Mylan, the company that came under fire this summer for systematically raising the price of the EpiPen, is caught up in another drug price scheme.

At first, I tried to bring about a socialist paradise by reducing the price of the EpiPen to $0. This meant I was bringing in no money and my investors were none too pleased. That approach went ...